Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)

Clinical trial NCT07272434 · RECRUITING

Trial details

NCT number: NCT07272434
Sponsor: MAXVAX Biotechnology Limited Liability Company
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Respiratory Syncytial Virus (RSV)

Start date: 2025-10-22
Primary completion: 2026-07-31
Enrollment: 25000

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.